A low score was associated with poor outcomes in patients who received standard induction therapy.
The estimated event-free survival rate was 28.6% at 2 years and 19.6% at 3 years.
Roughly 11% of AYA cancer survivors reported psychological distress 20 years or more after their cancer diagnosis.
No significant association was seen between maternal hormonal contraception use and CNS tumors in children younger than 20 years.
The findings of this study prompted a change in clinical practice.
Results from a phase 2 trial, if validated in a larger study, may be practice-changing, according to researchers.
Minimal residual disease in the bone marrow, detected via next-generation sequencing, was “highly predictive” of relapse after treatment with tisagenlecleucel.
Blinatumomab improved disease-free and overall survival.
The approval was based on data from the open-label, randomized phase 3 Inter-B-NHL Ritux 2010 trial.
Concerns, expressed early in the rollout, included lack of safety and efficacy data, particularly in children with cancer.
The risk of any cancer increased in association with first-trimester exposure.
Asian parents were more likely to report challenging relationships.
Stable disease was observed in 51.3% of patients.
Patients’ age, sex, and treatment-related symptoms, as well as mothers’ education level, were significantly associated with HRQOL.
Researchers were able to detect measurable residual disease at baseline in 64% of patients.
The suicide risk was significantly elevated for survivors alive beyond the age of 28 years.
The 5-year overall survival rate was 87%.
In a study of end-of-life care for children with cancer, healthcare resource use measures were seen as less important than were patient-reported outcomes.
The dose of chemotherapy and radiation, patient age, and timing of treatment were all associated with the risk of severe hearing loss.
More than one-third of tumors sequenced carried a high mutation burden.